T cell therapeutics are redefining what a prescription means. From autologous CAR-T to allogeneic off-the-shelf products, cell therapies require new paradigms for ordering, manufacturing, administering, and monitoring.
From approved products to next-generation platforms
Patient's own T cells engineered with chimeric antigen receptors. Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti are FDA-approved for blood cancers.
Off-the-shelf donor T cells engineered for universal use. CRISPR-edited to avoid graft-versus-host disease. Allogene, CRISPR Tx, and Precision leading development.
T cell receptors targeting intracellular tumor antigens. Adaptimmune's TECELRA (afamitresgene autoleucel) first TCR-T approved for solid tumors.
Tumor-infiltrating lymphocytes expanded and reinfused. Iovance's Lifileucel for melanoma. Natural tumor-reactive T cells without genetic engineering.
Next frontier targeting GD2, mesothelin, claudin18.2, and other solid tumor antigens. Armored CARs and logic-gated designs overcoming tumor microenvironment.
CD19 CAR-T showing remarkable efficacy in lupus and other autoimmune diseases. Potential for drug-free remissions with single treatment courses.
FDA-approved cellular therapeutics on the market
| Product | Company | Target | Indication | List Price |
|---|---|---|---|---|
| Kymriah | Novartis | CD19 | B-ALL, DLBCL, FL | $373K-$475K |
| Yescarta | Kite/Gilead | CD19 | LBCL, FL | $424K |
| Tecartus | Kite/Gilead | CD19 | MCL, B-ALL | $373K |
| Breyanzi | BMS/Juno | CD19 | LBCL, FL, MCL, CLL | $410K |
| Abecma | BMS/2seventy | BCMA | Multiple Myeloma | $419K |
| Carvykti | J&J/Legend | BCMA | Multiple Myeloma | $465K |
| Tecelra | Adaptimmune | MAGE-A4 (TCR) | Synovial Sarcoma | $727K |
| Amtagvi | Iovance | TIL | Melanoma | $515K |
TcellRx.com - Premium domain for the cell therapy pharmaceutical space. Ideal for specialty pharmacy, distribution, or therapeutic platforms.
Contact for Pricing